H2020Individual fellowship2019–2022

GenDels · Development of a new CRISPR-Cas3-based tool for large genomic deletions

Horizon 2020 — Marie Skłodowska-Curie Actions

Duration
2019-07-01 → 2022-06-30
EU contribution
€264,669
Participants
2
Scheme
MSCA-IF

Lines connect the coordinator with its partners.

Results in brief

Development of a new CRISPR-Cas3-based tool for large genomic deletions

The ability to genetically modify the DNA of model organisms (gene editing) is crucial for understanding biological processes and has wide implications for human health. The recent advent of a variety of gene-editing technologies has greatly enhanced our capabilities in modifying DNA of interest. Primary among these, a revolutionary technology called CRISPR-Cas9 has enabled changing DNA at an unprecedented scale in a variety of organisms, leading to impactful biological findings in all areas of basic and applied research. Tools based on this technology are suitable for a variety of gene editing applications, including generation of small deletions and insertions in genes which can help decipher the function of individual genes. Utilization of CRISPR-Cas9 as a tool to generate larger deletions is however limited. The ability to generate large deletions in the DNA of a variety of organisms is advantageous for multiple reasons: 1) vast regions of DNA (so-called "dark regions") with unknown function exist in all species, deletions of which could help better understand their functions, 2) the genomes of bacteria could be streamlined so that they function better for biotechnology purposes, 3) generating deletions in harmful bacteria could reveal the way they make their hosts sick 4) a system capable of generating large deletions could also be used to selectively kill dangerous bacteria. We have developed a technology based on an immune system called CRISPR-Cas3 that occurs naturally in some bacteria to overcome the lack of such a method. CRISPR-Cas3 systems are unique in that they not only cut DNA like other systems, but also loosen up its structure by unwinding it. They are then able to “chew” back this unwound DNA, leading to the destruction of long stretches of DNA. These properties have allowed CRISPR-Cas3 systems to generate large deletions when repurposed as tools. Previously, CRISPR-Cas3 systems had been overlooked as gene-editing tools, due to their relatively complicated architecture. We identified a more compact CRISPR-Cas3 system in a strain of the commonly studied bacterium Pseudomonas aeruginosa that consists of only 4 proteins that are needed to recognize and destroy targeted DNA sequences. This specific system, termed PaeCas3c, is ideal to repurpose as an editing tool, as it is less complex than other such systems. With this in mind, we achieved three broad goals: 1) we studied if and how PaeCas3c can make deletions in bacteria, 2) we developed the tool to be able to function in several different types of bacteria and 3) and we developed the system to be able to use it on more complex cells, such as model human cell lines.

Data: CORDIS, © European Union

Project objective

The advent of the revolutionary genome editing technique CRISPR-Cas9 has enabled targeted gene mutation, repression, and activation, facilitating impactful biological findings. However, Cas9 as an unbiased DNA deletion tool is limited in its ability to interrogate large regions of DNA of unknown function, because it predominantly generates very small (<20 bp) insertions and deletions at its target site. The capacity to rapidly and efficiently generate large genomic deletions does not currently exist and would be an extremely useful tool for research, allowing for rapid strain engineering of bacterial cells for synthetic biological and metabolic engineering purposes. Additionally, this technology would allow for the interrogation of large segments of non-coding DNA in human cells, much of which has unknown function, but whose variants are often associated with human disease. In this proposal, I aim to develop a Type I-C CRISPR-Cas system employing the Cas3 enzyme (completely distinct from Cas9), which naturally possess coupled nuclease and helicase activity, for high-throughput gene-editing purposes in various prokaryotic, as well as human cells. My preliminary results have shown that this is a credible approach, as I have been able to generate individually, as well as in combination, multiple deletions in bacterial organisms exceeding 60 kb in size. A focal point of the proposal is to adapt this system for use in human cells, which would provide a novel basic research tool with unprecedented capabilities and also could be utilized in human health-related applications. The proposal aims to address this later possibility by utilizing the developed system to treat human cell lines infected with difficult-to-treat pathogenic viruses.

Original text from CORDIS.

Participants

  • EUROPEAN MOLECULAR BIOLOGY LABORATORY · HeidelbergCoordinatorGermany
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA · OaklandUnited States

Links

Data: CORDIS, © European Union